Varex Imaging Faces Financial Strain Amidst Potential Goodwill Impairment Charges
Varex Imaging Corporation is facing financial risks due to potential goodwill impairment charges, which could negatively impact earnings. The company recently recorded a $93.9 million impairment charge for its Medical unit, influenced by stock price decline and external pressures. Further impairment charges may threaten financial health. Wall Street rates VREX stock as Moderate Buy.
Varex Imaging Corporation (VREX) has disclosed a new risk, in the Accounting & Financial Operations category.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Varex Imaging Corporation faces significant financial risk due to potential impairment charges related to its goodwill, which stood at $198.4 million as of October 3, 2025. The company is required to conduct annual tests on intangible assets with indefinite lives, including goodwill, and may need to record impairment charges that could negatively impact earnings or increase losses. A recent example includes a $93.9 million goodwill impairment charge recorded for its Medical reporting unit, driven by factors such as a decrease in stock price and market capitalization, as well as external pressures like tariffs and MOFCOM Investigations. The sensitivity of their goodwill impairment analysis to key assumptions suggests that further impairment charges could occur, posing a threat to the company’s financial health and operational results.
Overall, Wall Street has a Moderate Buy consensus rating on VREX stock based on 2 Buys and 1 Hold.
To learn more about Varex Imaging Corporation’s risk factors, click here.
